UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 15, 2009

 

 

DRAGON PHARMACEUTICAL INC.

(Exact name of registrant as specified in its charter)

 

 

 

 

 

(604) 669-8817

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

 

 

 

 

Section 2 – Financial Information

 

 

          On May 15, 2009, Dragon Pharmaceutical Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2009. A copy of the press release is attached hereto as Exhibit 99.1.

 

Section 7.01- Regulation FD Disclosure

 

          Ms. Maggie Deng, Chief Operating officer, and Mr. Garry Wong, Chief Financial Officer, will participate in the Oppenheimer 3rd Annual China Dragon Call Conference to be held on May 19 - 21, 2009, in the Executive Conference Center at Oppenheimer’s 300 Madison Avenue offices in New York City.

          Mr. Garry Wong will present the Company’s business overview including core product lines, competitive strengths and key growth strategies at 9:40 a.m. (Eastern Daylight Time) on May 19, 2009, in the Gramercy Room and will be available to answer investor questions after the presentation.

          The investor presentation for the Oppenheimer conference is being furnished through this Form 8-K and will be posted on Dragon’s website at www.dragonpharma.com on the same day as the presentation.

 

Section 9 – Financial Statements and Exhibits

 

 

 

 

 

The information set forth under Item 2.02 and 7.01 of this Form 8-K and Exhibits 99.1 and 99.2 attached hereto are furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, and shall not be deemed incorporated by reference in any filing with the Securities and Exchange Commission under the Securities Exchange Act of 1934 or the Securities Act of 1933, whether made before or after the date hereof and irrespective of any general incorporation by reference language in any filing.

 

Portions of this report constitute “forward-looking statements” defined by federal law. Although the Company believes any such statements are based on reasonable assumptions, there is no assurance that the actual outcomes will not be materially different. Any such statements are made in reliance on the “safe harbor” protections provided under the Private Securities Litigation Reform Act of 1995. Additional information about issues that could lead to material changes in the Company’s performance is contained in the Company’s filings with the Securities and Exchange Commission and may be accessed at www.sec.gov.

 

SIGNATURE

 

          Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

/s/ Maggie Deng
Maggie Deng

Chief Operating Officer

 

 

 

 

 

 

 

EXHIBIT INDEX